UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

slc26a3 (dra)-deficient Mice Display Chloride-losing Diarrhea, Enhanced Colonic Proliferation, and Distinct Up-regulation of Ion Transporters in the Colon

The Journal of biological chemistry, 2006-12, Vol.281 (49), p.37962-37971

2006

Volltextzugriff (PDF)

Decreased Expression of Colonic Slc26a3 and Carbonic Anhydrase IV as a Cause of Fatal Infectious Diarrhea in Mice

Infection and Immunity, 2009-09, Vol.77 (9), p.3639-3650

2009

Volltextzugriff (PDF)

Protein localization of SLC26A2 (DTDST) in rat kidney

Histochemistry and cell biology, 2010-05, Vol.133 (5), p.541-547

2010

Volltextzugriff (PDF)

The colon anion transporter, Down-regulated in Adenoma, induces growth suppression that is abrogated by E1A

Cancer research (Chicago, Ill.), 2002-09, Vol.62 (17), p.5083-5088

2002

Volltextzugriff (PDF)

CaSm : An Sm-like protein that contributes to the transformed state in cancer cells

Cancer research (Chicago, Ill.), 1997-07, Vol.57 (14), p.2961-2965

1997

Volltextzugriff (PDF)

HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014–2015

The New England journal of medicine, 2016-07, Vol.375 (3), p.229-239

2016

Volltextzugriff (PDF)

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

The New England journal of medicine, 2011-06, Vol.364 (26), p.2507-2516

2011

Volltextzugriff (PDF)

Changing epidemiology of candidaemia in Australia

Journal of antimicrobial chemotherapy, 2017-04, Vol.72 (4), p.1103-1108

2017

Volltextzugriff (PDF)

Financial Behaviors and Experiences of Financial Loss in those with Alzheimer’s disease and Frontotemporal Dementia: Preliminary findings from a survey

Alzheimer's & dementia, 2023-06, Vol.19 (S4), p.n/a

2023

Volltextzugriff (PDF)

Changing epidemiology of candidaemia in Australia

Journal of antimicrobial chemotherapy, 2017-04, Vol.72 (4), p.1270-1270

2017

Volltextzugriff (PDF)

Time-to-positivity in bloodstream infection for Candida species as a prognostic marker for mortality

Medical mycology (Oxford), 2023-04, Vol.61 (4)

2023

Volltextzugriff (PDF)

Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation

The Journal of pharmacology and experimental therapeutics, 2009-12, Vol.331 (3), p.1042

2009

Volltextzugriff (PDF)

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

Journal of medicinal chemistry, 2009-10, Vol.52 (19), p.5803-5815

2009

Volltextzugriff (PDF)

Methodology to develop and evaluate a semantic representation for NLP

AMIA ... Annual Symposium proceedings, 2009-11, Vol.2009, p.271-275

2009

Volltextzugriff (PDF)

Pharmacological Characterization of 3-[3- tert -Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

The Journal of pharmacology and experimental therapeutics, 2009-12, Vol.331 (3), p.1042-1050

2009

Volltextzugriff (PDF)

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

Journal of medicinal chemistry, 2009-10, Vol.52 (19), p.5803-5815

2009

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(8)
Animals
(7)
Male
(6)
Biological And Medical Sciences
(5)
Female
(5)
Mice
(5)
Infectious Diseases
(4)
Medical Sciences
(3)
Microbiology
(3)
Pharmacology & Pharmacy
(3)
Rats
(3)
5-Lipoxygenase-Activating Proteins
(2)
Adult
(2)
Antiporters - Genetics
(2)
Antiporters - Physiology
(2)
Asthma - Drug Therapy
(2)
Carrier Proteins - Antagonists & Inhibitors
(2)
Chlorides - Metabolism
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

slc26a3 (dra)-deficient Mice Display Chloride-losing Diarrhea, Enhanced Colonic Proliferation, and Distinct Up-regulation of Ion Transporters in the Colon

Decreased Expression of Colonic Slc26a3 and Carbonic Anhydrase IV as a Cause of Fatal Infectious Diarrhea in Mice

Protein localization of SLC26A2 (DTDST) in rat kidney

The colon anion transporter, Down-regulated in Adenoma, induces growth suppression that is abrogated by E1A

CaSm : An Sm-like protein that contributes to the transformed state in cancer cells

HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014–2015

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Changing epidemiology of candidaemia in Australia

Financial Behaviors and Experiences of Financial Loss in those with Alzheimer’s disease and Frontotemporal Dementia: Preliminary findings from a survey

Changing epidemiology of candidaemia in Australia

Time-to-positivity in bloodstream infection for Candida species as a prognostic marker for mortality

Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

Methodology to develop and evaluate a semantic representation for NLP

Pharmacological Characterization of 3-[3- tert -Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

Suchergebnisse filtern